The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC) (2018)
- Authors:
- Autor USP: CHAMMAS, ROGER - FM
- Unidade: FM
- DOI: 10.1590/1414-431X20177214
- Subjects: ANTINEOPLÁSICOS; BIOFARMACOLOGIA; NEOPLASIAS; ANTICORPOS; FÁRMACOS IMUNOSSUPRESSORES
- Language: Inglês
- Imprenta:
- Source:
- Título: Brazilian journal of medical and biological research
- ISSN: 0100-879X
- Volume/Número/Paginação/Ano: v. 51, n. 3, article ID e7214, 7p, 2018
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
FERNANDES, G. S. et al. The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC). Brazilian journal of medical and biological research, v. 51, n. 3, 2018Tradução . . Disponível em: https://doi.org/10.1590/1414-431X20177214. Acesso em: 25 jan. 2026. -
APA
Fernandes, G. S., Sternberg, C., Lopes, G., Chammas, R., Gifone, M. A. C., Gil, R. A., & Araujo, D. V. (2018). The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC). Brazilian journal of medical and biological research, 51( 3). doi:10.1590/1414-431X20177214 -
NLM
Fernandes GS, Sternberg C, Lopes G, Chammas R, Gifone MAC, Gil RA, Araujo DV. The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC) [Internet]. Brazilian journal of medical and biological research. 2018 ; 51( 3):[citado 2026 jan. 25 ] Available from: https://doi.org/10.1590/1414-431X20177214 -
Vancouver
Fernandes GS, Sternberg C, Lopes G, Chammas R, Gifone MAC, Gil RA, Araujo DV. The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC) [Internet]. Brazilian journal of medical and biological research. 2018 ; 51( 3):[citado 2026 jan. 25 ] Available from: https://doi.org/10.1590/1414-431X20177214 - Cellular prion protein participation in experimental tumorigenesis
- Initial analysis of melanoma progression using a proteomic approach
- Mannose receptor 1 expression does not determine the uptake of high-density mannose dendrimers by activated macrophages populations
- The role of kinin receptors in cancer and therapeutic opportunities
- FGF-2 Motogenic, but not mitogenic, activity depends on glycosphingolipid composition of melannocyte cell membranes
- The role of galectin-3 on B cell differentiation: an increase of B precursors in bone marrow compartments
- Anti-tumor effect of endostatin mediated by retroviral gene transfer in mice bearing renal cell carcinoma
- Guanosine promotes B16F10 melanoma cell differentiation through PKC–ERK 1/2 pathway
- Fucoidan from Spatoglossum schroederi promotes B16-F10 malignancy features modulation and antimelanoma in vivo activities
- Galectin-3 gene is silenced by epigenetic mechanisms along melanoma progression
Informações sobre o DOI: 10.1590/1414-431X20177214 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
